8-K: Fortress Biotech Pauses Preferred Stock Dividends to Bolster Financial Flexibility

Fortress Biotech has announced a temporary halt to its monthly dividend payments on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock to preserve cash ahead of potential regulatory approvals.

Summary

• Fortress Biotech has decided to pause its monthly dividend payments of $0.1953125 per share on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock.
• This pause will defer approximately $0.7 million in cash dividend payments each month.
• Dividends will continue to accrue and cumulate until they are authorized or declared.
• The board intends to regularly review this decision based on the company's profitability and cash flow.
• The company is anticipating up to three regulatory approvals in the next 12 months for DFD-29, cosibelimab, and CUTX-101.
• A fourth BLA filing for CAEL-101 is expected as early as 2025.
• AstraZeneca expects the FDA to accept its BLA submission of CAEL-101 for review as early as 2025, which could lead to approval and commercial milestone payments to Fortress.
• Cyprium Therapeutics, a subsidiary, will retain 100% ownership of any priority review voucher issued for CUTX-101.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the pause in dividend payments, which is a negative signal for income-focused investors. However, the potential for multiple regulatory approvals and future milestone payments provides some positive outlook.

Positives

• The pause in dividend payments will provide the company with increased financial flexibility.
• The company anticipates multiple near-term regulatory milestones, including potential approvals for three key drugs.
• The company is positioned to receive potential milestone payments from AstraZeneca related to CAEL-101.
• Cyprium Therapeutics retaining full ownership of the priority review voucher for CUTX-101 is a positive for the subsidiary.

Negatives

• The pause in dividend payments will negatively impact investors who rely on the income from the preferred stock.
• The company's decision to pause dividends suggests potential concerns about current cash flow or profitability.

Risks

• The company's growth strategy, financing, and strategic agreements are subject to risks.
• The ongoing UTRF litigation and indemnification of Caelum pose potential risks.
• The company needs substantial additional funds and faces uncertainties relating to financings.
• There are risks associated with identifying, acquiring, closing, and integrating product candidates.
• The company faces risks related to attracting, integrating, and retaining key personnel.
• The products under development are in early stages and subject to uncertainties.
• There are uncertainties related to preclinical and clinical testing.
• The timing and likelihood of a BLA being submitted for CAEL-101 is uncertain.
• The company's ability to obtain regulatory approval for products under development is not guaranteed.
• The company's ability to successfully commercialize products is subject to risks.
• There are uncertainties related to the granting of any priority review voucher for CUTX-101.
• The company's ability to secure and maintain third-party manufacturing, marketing, and distribution is subject to risks.
• Government regulation, patent and intellectual property matters, and competition pose risks.

Future Outlook

The company anticipates potential regulatory approvals for DFD-29, cosibelimab, and CUTX-101 in the next 12 months and a BLA filing for CAEL-101 as early as 2025. The company will regularly assess its profitability and cash flow to determine when to lift the dividend pause.

Management Comments

• Lindsay A. Rosenwald, M.D., Fortress Chairman, President and Chief Executive Officer, stated that the company could receive up to three regulatory approvals in the next 12 months.
• He also mentioned the potential for a fourth BLA filing as early as 2025.
• He noted that the company is pausing the preferred dividend payments to maintain financial flexibility ahead of multiple potential near-term milestones.

Industry Context

This announcement comes as the biopharmaceutical industry is closely watching for regulatory approvals and milestone achievements. The decision to pause dividends to maintain financial flexibility is not uncommon for companies in this sector, especially those with multiple potential near-term catalysts.

Comparison to Industry Standards

• Many biopharmaceutical companies, especially those in the development stage, prioritize cash preservation to fund research and development activities.
• Pausing dividends is a measure often taken to ensure sufficient capital for upcoming milestones, such as regulatory submissions and commercialization efforts.
• Companies like Amgen and Gilead Sciences, while larger and more established, also manage their cash flow carefully, balancing shareholder returns with investment in future growth.
• The potential for multiple regulatory approvals in the next 12 months is a significant catalyst for Fortress, similar to other companies with promising drug pipelines like BioMarin and Vertex Pharmaceuticals.

Stakeholder Impact

• Shareholders of the Series A Preferred Stock will be negatively impacted by the pause in dividend payments.
• The company's employees may be impacted by the company's financial decisions.
• The company's customers and suppliers may be impacted by the company's financial decisions.
• The company's creditors may be impacted by the company's financial decisions.

Next Steps

• The Board will regularly revisit its decision regarding the monthly dividend.
• The company will assess its profitability and cash flow to determine when the pause should be lifted.
• The company will continue to pursue regulatory approvals for DFD-29, cosibelimab, and CUTX-101.
• The company will work towards a BLA filing for CAEL-101.

Key Dates

Keywords

Fortress Biotech, Preferred Stock, Dividends, Regulatory Approvals, Financial Flexibility, Biopharmaceutical, DFD-29, cosibelimab, CUTX-101, CAEL-101, Priority Review Voucher